Clinical Trial Detail

NCT ID NCT03263650
Title Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

prostate carcinoma

Therapies

Cabazitaxel + Carboplatin

Olaparib

Age Groups: senior adult

No variant requirements are available.